Infinitopes
Infinitopes is a pioneering cancer research organization focused on developing revolutionary cancer vaccines through its Infinitopes Precision Immunomics™ platform. The company leverages advanced laboratory techniques, computational methods, and machine learning workflows to identify highly-expressed tumor antigens, aiming to enhance T cell immunity and optimize treatment timing for patients. With a strong foundation in immuno-oncology and a team experienced in over 70 clinical trials, Infinitopes is set to initiate its first-in-human trial in 2024, positioning itself as a leader in the cancer vaccine market.
Infinitopes
Infinitopes is a pioneering cancer research organization focused on developing revolutionary cancer vaccines through its Infinitopes Precision Immunomics™ platform. The company leverages advanced laboratory techniques, computational methods, and machine learning workflows to identify highly-expressed tumor antigens, aiming to enhance T cell immunity and optimize treatment timing for patients. With a strong foundation in immuno-oncology and a team experienced in over 70 clinical trials, Infinitopes is set to initiate its first-in-human trial in 2024, positioning itself as a leader in the cancer vaccine market.
TL;DR
Stage: Clinical-stage (FIH trial initiated 2024)
Technology: Infinitopes Precision Immunomics™ antigen-discovery platform (AI/ML + vector delivery)
Founded: 2021 (Oxford/CRUK spinout)
Recent funding: Seed expanded to $35.1M (Jan 21, 2026); prior £12.8M seed (Apr 2024)
HQ / Base: Oxford (BioEscalator)
Company Overview
Problem Domain
Immuno-oncology — therapeutic cancer vaccines and antigen discovery
Founded
2021
Industry
Biotechnology
Funding Track Record
£12.8M
Announced oversubscribed £12.8M seed financing in April 2024
USD 15.4M (additional); total USD 35.1M reported
Expanded seed financing to $35.1M with participation from Macmillan Cancer Support and others
Investor Signal
“Includes specialist life-science and cancer-focused investors such as Octopus Ventures, Amplify Bio, Cancer Research Horizons, Macmillan Cancer Support, Manta Ray Ventures and others”